SCHEMBL12436733

SCHEMBL12436733

CC(=O)C1CCC(NC(=O)c2ccccn2)CC1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMYD3 Q9H7B4 1/20 0.64
GRM5 P41594 8/20 0.63
KDM4E B2RXH2 2/20 0.55
GAA P10253 2/20 0.55
KMT2A Q03164 1/20 0.55
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
ALDH1A1 P00352 2/20 0.49
EGFR P00533 1/20 0.49
ERBB2 P04626 1/20 0.49
MET P08581 1/20 0.49
KDR P35968 1/20 0.49
MERTK Q12866 1/20 0.49
CRBN Q96SW2 1/20 0.49
TP53 P04637 1/20 0.49
PKM P14618 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.48
MAPT P10636 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22722015 1.00 SMYD3 (0.64) SMYD3GRM5KDM4EGAAKMT2A
SCHEMBL2241357 0.89 GRM5 (0.77) SMYD3GRM5KDM4EGAAKMT2A
SCHEMBL25393971 0.87 SMYD3 (0.65) SMYD3GRM5KDM4EGAAKMT2A
SCHEMBL30599111 0.86 SMYD3 (0.61) SMYD3GRM5KDM4EGAAKMT2A
SCHEMBL25395633 0.86 SMYD3 (0.61) SMYD3GRM5KDM4EGAAKMT2A
SCHEMBL14492281 0.85 GRM5 (0.67) SMYD3GRM5KDM4EGAAKMT2A
SCHEMBL14506761 0.85 GRM5 (0.67) SMYD3GRM5KDM4EGAAKMT2A
SCHEMBL30043946 0.84 GRM5 (0.68) SMYD3GRM5KDM4EGAAKMT2A
SCHEMBL2246381 0.83 GRM5 (0.82) SMYD3GRM5KDM4EGAAKMT2A
SCHEMBL16394406 0.83 GRM5 (0.88) SMYD3GRM5KDM4EGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
US-RE48334-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-12-01 US disclosed
EP-2336105-B9 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL (JP) 2014-09-17 EP disclosed
EP-2336105-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL (JP) 2014-02-12 EP disclosed
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed
EP-2336105-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME Takeda Pharmaceutical Company Limited (JP) 2011-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME NTSR2, BDKRB1, AVPR1B SMYD3 2545/4885GRM5 422/4885KDM4E 4083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.